Retatrutide,
on the record.
GLP-1 / GIP / glucagon triple agonist·Tracking
Triple agonist (GLP-1 / GIP / glucagon) in Phase 3 trials for obesity. Not yet FDA approved.
Not yet available. Retatrutide is in active clinical study. We track every trial, paper, and FDA filing. When it crosses into prescribable, you'll know first.
Also known as
LY3437943
01
The evidence.
4 PubMed
5 ClinicalTrials.gov
0 openFDA
90-day search interest
PubMed·Jun 1, 2026
Obesity pharmacotherapy reimagined: The era of multi-receptor agonists and next-generation metabolic modulators, perspectives and controversies.
Lempesis IG, Dalamaga M
PubMed·May 22, 2026
Dysesthesia associated with GLP-1 agonist therapies: data-mining analysis and literature review.
Laroche ML, Géniaux H, Jardou M
ClinicalTrials.gov·May 22, 2026
A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight
Eli Lilly and Company
ClinicalTrials.gov·May 22, 2026
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight
Eli Lilly and Company
ClinicalTrials.gov·May 22, 2026
A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease
Eli Lilly and Company
ClinicalTrials.gov·May 22, 2026
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
Eli Lilly and Company
ClinicalTrials.gov·May 20, 2026
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain
Eli Lilly and Company
PubMed·May 14, 2026
Retatrutide And Lipid And Metabolite Profiles In Participants With Obesity With Or Without Type 2 Diabetes.
Pearson MJ, Willency JA, Lin Y et al.
PubMed·May 11, 2026
Triple Hormone Receptor Agonism: The Role of Retatrutide in Addressing Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Comprehensive Review.
Pillai AA, Godin SL, Frishman WH et al.
RetatrutideGLP-1 / GIP / glucagon triple agonist
Notify me